MassHealth Drug Utilization Review (DUR) Program

333 South Street

Shrewsbury, MA 01545

(800) 745-7318 (phone)

(877) 208-7428 (fax)

DUR BOARD

Quarterly Meeting

December 11, 2019

AGENDA

1. Welcome and Introductory Remarks
2. Introduction of New Board Members
3. Guest Forum

A Lilly pharmaceuticals representative will offer testimony on nasal glucagon.

1. Biosimilar Update: Pipeline Trends and Regulatory Updates

The update will provide a brief overview of clinical and/or regulatory updates regarding select pharmaceutical biosimilar pipeline agents that are newly marketed or in late-stage development.

1. **PARP (Poly [ADP-ribose]polymerase) Inhibitors** Quality Assurance Analysis

This overview is an evaluation of current medical literature and will provide a brief overview of guideline recommendations in this disease state.

1. Infectious Disease Hot Topics: New Trends in Hepatitis C Virus and Human Immunodeficiency Virus Treatment

This overview is an evaluation of current medical literature and newly approved agents and will provide a brief overview of guideline recommendations in these disease states.

1. MHDL Update

The MHDL Overview will include new additions, changes in Prior Authorization (PA) status, and related attachment updates to be implemented with a future publication rollout.

1. DUR Operational Update

The DUR Operational Overview will include statistics associated with Prior Authorization (PA) review and PA response, and Call Center metrics.

1. MassHealth Update

The MassHealth Update is a brief summary of recent developments in MassHealth in the context of pharmacy, managed care, and public health.

1. Clinical Team Update

The Clinical Team Update will include an overview of projects and accomplishments of the clinical pharmacist team of the MassHealth Drug Utilization Review Program.

*(time permitting)*

*Location: DUR Time: 6:00p.m. – 8:00p.m.*

 *Amphitheater*

*333 South St*

*Shrewsbury, MA*

*The Massachusetts Commission for the Deaf and Hard of Hearing will assist with arrangements for a sign language interpreter. The Commission may be reached at (617) 740-1600 VOICE and (617) 740-1700 TTY.*

***Next DUR Board (open meeting): March 11, 2020***